Lipid Disturbances in Adolescents Treated With Second-Generation Antipsychotics: Clinical Determinants of Plasma Lipid Worsening and New-Onset Hypercholesterolemia.

Détails

Ressource 1Demande d'une copie Sous embargo jusqu'au 29/10/2019.
Etat: Public
Version: Author's accepted manuscript
Licence: Non spécifiée
ID Serval
serval:BIB_B98038AE6722
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Lipid Disturbances in Adolescents Treated With Second-Generation Antipsychotics: Clinical Determinants of Plasma Lipid Worsening and New-Onset Hypercholesterolemia.
Périodique
The Journal of clinical psychiatry
Auteur(s)
Delacrétaz A., Vandenberghe F., Glatard A., Dubath C., Levier A., Gholam-Rezaee M., Holzer L., Ambresin A.E., Conus P., Eap C.B.
ISSN
1555-2101 (Electronic)
ISSN-L
0160-6689
Statut éditorial
Publié
Date de publication
09/04/2019
Peer-reviewed
Oui
Volume
80
Numéro
3
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Lipid disturbances following treatment with second-generation antipsychotics (SGAs) represent a major health concern. A previous study determined that early changes of plasma lipid levels ≥ 5% during the first month of treatment with SGAs predicts further lipid worsening and development of dyslipidemia. This current study aimed to determine the proportion of adolescents with early lipid changes ≥ 5% and who develop dyslipidemia during SGA treatment.
Data were obtained from a 1-year longitudinal study ongoing since 2007 including 53 adolescent psychiatric (ICD-10) patients (median age 16.5 years; interquartile range [IQR], 14.8-17.5 years) whose metabolic parameters were monitored prospectively during treatment. Plasma lipid levels (total, low-density lipoprotein, high-density lipoprotein [HDL-C], and non-high-density lipoprotein cholesterol and fasting triglycerides ) were measured at baseline and after 1, 3, and/or 12 months of SGA treatment.
Half (n = 26; 49%) the adolescents had an early increase of total cholesterol levels by 5% or more during the first month of treatment, and one-third (n = 8/24; 33%) developed new-onset hypercholesterolemia during the first year of treatment. Hypercholesterolemia developed more frequently in female patients (P = .01) and in patients with an early increase of total cholesterol ≥ 5% (P = .02). Finally, patients whose HDL-C levels decreased by ≥ 5% during the first month of treatment had a larger HDL-C worsening after 3 months of treatment as compared with patients with early decrease of HDL-C by < 5% (P = .02).
This study underlines the importance of prospectively monitoring metabolic parameters in adolescents after the introduction of SGAs.
Pubmed
Web of science
Création de la notice
02/05/2019 13:40
Dernière modification de la notice
20/08/2019 16:27
Données d'usage